ORKA Oruka Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why ORKA matters now
Oruka Therapeutics, Inc. (ORKA) is a US stock in Healthcare. The latest InvestLog snapshot shows $84.40 with -0.12% on the session and $3.16B in market capitalization; recent performance reads 1-month +25.81% and YTD +138.67%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-31.8M, and EPS of $-0.58. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.4%.
The latest indexable market news headline is "Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $155.50; recent insider activity includes Quinlan Paul T filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.20
P/S
0.00
EV/EBITDA
-22.92
DCF Value
$0.90
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.0%
ROA
-23.0%
ROIC
-27.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-31.8M | $-0.58 |
| Q4 2025 | $0.00 | $-29.6M | $-0.54 |
| FY 2025 | $0.00 | $-105.4M | $-2.31 |
| Q3 2025 | $0.00 | $-30.3M | $-0.69 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$149.50
Target (Median)
$155.50
Target Range
$100.00 - $200.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.30
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.